• Blog
  • Pricing
  • Contact
  • FAQ
Sign InSign Up
AI Agent for Financial MarketsAsk anything. Our AI Agent brings real-time data and full market coverage.Open chat
MarketsStocksCryptoForexCommoditiesCalendarInsiders
KYMR

KYMR

Kymera Therapeutics, Inc.

NASDAQHealthcareBiotechnologyUS

USD73.21

+1.92 (+2.69%)

Rating:C-

Company Profile

CEO

Nello Mainolfi

IPO Date

2020-08-21

Sector

Healthcare

Industry

Biotechnology

Exchange

NASDAQ

Country

US

Market Metrics

Open

$70.99

Prev. Close

$71.29

Day Low

$69.48

Day High

$73.94

52W Low

$36.65

52W High

$103.00

Market Cap

$6.02B

Volume

0.85M

OverviewFinancialsRatingsInsidersSentimentsChart Patterns
News SentimentBullish

Articles

10

Avg Positive

43.1%

Avg Negative

1.1%

Avg Neutral

55.7%

News Feed

Kymera Therapeutics Presents New Preclinical Data on STAT3 Degraders Showing Antitumor Activity in STAT3 Mutant and Wild-Type Peripheral T-Cell Lymphoma at 13th Annual T-Cell Lymphoma Forum

GlobeNewsWire·7/12/2021·↑ positive

Kymera Therapeutics Announces Pricing of Upsized Public Offering of Common Stock

GlobeNewsWire·6/30/2021·↑ positive

Kymera Therapeutics Seeks To Raise Capital Via 4M Shares Equity Offering To Fund Oncology Franchises

Benzinga·6/29/2021·↑ positive

Kymera Therapeutics Announces Proposed Public Offering of Common Stock

GlobeNewsWire·6/28/2021·↑ positive

KYMR Stock Price Increases Over 8% Pre-Market: Why It Happened

Pulse2·6/28/2021·↑ positive

Kymera Therapeutics Announces Positive Interim Results from Single Ascending Dose Phase 1 Trial of KT-474 Demonstrating Degrader Proof-of-Mechanism

GlobeNewsWire·6/28/2021·↑ positive

Kymera Therapeutics Appoints Elaine Caughey, MBA, as Chief Business Officer

GlobeNewsWire·6/21/2021·↑ positive

Kymera Therapeutics' KT-413 Shows Encouraging Preclinical Anti-Cancer Activity

Benzinga·6/21/2021·↑ positive

Kymera Therapeutics to Participate in Goldman Sachs 42nd Annual Global Healthcare Conference

GlobeNewsWire·6/2/2021·↑ positive

Kymera Therapeutics Honored by Boston Business Journal as a 2021 Best Places to Work Company

GlobeNewsWire·4/19/2021·↑ positive